Serendip today
The company was founded in 2023 in Strasbourg and builds on two decades of academic research in the underlying technology.
Its creation is a remarkable story of a successful meeting between two academic researchers—experts in plant biology and virology—and a pharmaceutical industry specialist with deep experience in managing product development and industrializing bioprocesses.
Team


Scientific
advisory board

PhD
François GHIRINGHELLI
Oncologist and clinical expert at CGFL
(Dijon, France)
Head of immunotherapy innovations and CLIP² clinical platform.
Expert in immunology, preclinical and clinical studies.

PhD
Jean-Pierre ABASTADO
Independent immuno-oncology consultant
Former R&D director at Servier, experienced expert in pharmaceutical industry, especially in designing preclinical and clinical studies.

PhD
Sébastien APCHER
Principal Investigator at Institute Gustave Roussy
(Villejuif, France)
Immuno-oncology expert in neoantigens discovery and validation.

PhD
Hélène DUMORTIER
Principal Investigator at IBMC
(Strasbourg, France)
Immunology expert, especially in Proof of Concepts.

PhD
Christophe RITZENHALER
Principal Investigator at IBMP
(Strasbourg, France)
Plant biology expert especially in engineering the VLP and optimizing the plant-based expression system.
Support

Facility

Finance
Serendip is currently seeking 3 million € in private investment to fund collaborative feasibility studies, as well as the pharmacology and toxicology studies necessary to de-risk safety aspects for our partners.
Over the next three years, Serendip will focus on demonstrating the versatility, efficacy, safety, and commercial potential of its platform.
If you’re interested in exploring investment opportunities, feel free to reach out via the contact form. Investments in deeptech innovation companies like Serendip may qualify for tax incentives, offering up to a 50% reduction on the invested amount.

News

La jaune et la rouge
(article, April 2025)

Challenges, les 100 startups où investir en 2025
(article, April 2025)

Matwin Board of pharmaceutical companies
(prize, April 2025)

La gazette du laboratoire
(article, April 2025)

Matwin Board of Investors
(prize, April 2025)

CNRS innovation
(article, March 2024)

Le journal des entreprises
(article, December 2023)